Thread by @kgromax

$CYDY is making bad news hard to understand for its shareholders

Before the open on Monday I WILL PROVE that the FDA just excluded from eIND ALL THE INTUBATED PATIENTS from its CD12 trial

Eg even the 4 anecdotal patients from the paper co-written by its CEO below WOULD BE OUT

https://twitter.com/rossoscud/status/1344646492892622849

Remember when I correctly infered in Oct. based on cross-arms mortality data disclosed by $CYDY that CD12 trial would not be stopped for early efficacy?
With the proof above I will infer again with some maths that CD12 is heading toward failure for both severes and criticals

For $CYDY lovers, a quick primer:
« …SAEs that are consequences of the underlying disease…would be reportable…however, if an aggregate analysis indicated that the events were occurring more frequently in the drug treatment group than in a control group"
fda.gov/media/94879/do…

which means if the $CYDY trial DSMC had seen more deaths in the Leronlimab arm (vs Standard Of Care arm) for intubated patients, they would have had to report it to the FDA. Not required to unblind patient-level data though: as this document says, aggregate analysis is sufficient

To sum it up, 3 $CYDY things to discuss on Monday (have some work to close so maybe ~10 EST)
1) What is going on with the FDA and CD12 intubated patients?
2) Could the FDA obtain early access to trial data?
3) If intubated segment failed, can the trial remainder still succeed?

An as an added bonus this will include a list of official questions for @CytoDyn next conference call this week, in particular regarding whether its Chief Financial Officer knew a very specific fact when he planned his stock sale on Nov 12th
$CYDY

$CYDY just corrected its past PR this morning, retracting the eIND criteria it communicated earlier. Consequently, I retract my analysis